Research ExplorerPublicationsPrevention and treatment of relapse after stem cell transpla...

Prevention and treatment of relapse after stem cell transplantation by cellular therapies

Standard

Prevention and treatment of relapse after stem cell transplantation by cellular therapies. / Falkenburg, Fred; Ruggiero, Eliana; Bonini, Chaira; Porter, David; Miller, Jeff; Malard, Floran; Mohty, Mohamad; Kröger, Nicolaus; Kolb, Hans Jochem.

In: BONE MARROW TRANSPL, Vol. 54, No. 1, 01.2019, p. 26-34.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Falkenburg, F, Ruggiero, E, Bonini, C, Porter, D, Miller, J, Malard, F, Mohty, M, Kröger, N & Kolb, HJ 2019, 'Prevention and treatment of relapse after stem cell transplantation by cellular therapies', BONE MARROW TRANSPL, vol. 54, no. 1, pp. 26-34. https://doi.org/10.1038/s41409-018-0227-0

APA

Falkenburg, F., Ruggiero, E., Bonini, C., Porter, D., Miller, J., Malard, F., Mohty, M., Kröger, N., & Kolb, H. J. (2019). Prevention and treatment of relapse after stem cell transplantation by cellular therapies. BONE MARROW TRANSPL, 54(1), 26-34. https://doi.org/10.1038/s41409-018-0227-0

Vancouver

Falkenburg F, Ruggiero E, Bonini C, Porter D, Miller J, Malard F et al. Prevention and treatment of relapse after stem cell transplantation by cellular therapies. BONE MARROW TRANSPL. 2019 Jan;54(1):26-34. https://doi.org/10.1038/s41409-018-0227-0

Bibtex

@article{0aa73fa230ba46f5b11a229b9650b531,
title = "Prevention and treatment of relapse after stem cell transplantation by cellular therapies",
abstract = "Despite recent advances in reducing therapy-related mortality after allogeneic stem cell transplantation (alloSCT) relapse remains the major cause of treatment failure and little progress has been achieved in the last decades. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg/Germany in November 2016 international experts presented and discussed recent developments in the field. Here, the potential of cellular therapies including unspecific and specific T cells, genetically modified T cells, CAR-T cells, NK-cells, and second allografting in prevention and treatment of relapse after alloSCT are summarized.",
keywords = "Journal Article, Stem Cell Transplantation, Recurrence, Allografts, Immunotherapy, Adoptive, Humans, Killer Cells, Natural/transplantation, T-Lymphocytes/transplantation",
author = "Fred Falkenburg and Eliana Ruggiero and Chaira Bonini and David Porter and Jeff Miller and Floran Malard and Mohamad Mohty and Nicolaus Kr{\"o}ger and Kolb, {Hans Jochem}",
year = "2019",
month = jan,
doi = "10.1038/s41409-018-0227-0",
language = "English",
volume = "54",
pages = "26--34",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Prevention and treatment of relapse after stem cell transplantation by cellular therapies

AU - Falkenburg, Fred

AU - Ruggiero, Eliana

AU - Bonini, Chaira

AU - Porter, David

AU - Miller, Jeff

AU - Malard, Floran

AU - Mohty, Mohamad

AU - Kröger, Nicolaus

AU - Kolb, Hans Jochem

PY - 2019/1

Y1 - 2019/1

N2 - Despite recent advances in reducing therapy-related mortality after allogeneic stem cell transplantation (alloSCT) relapse remains the major cause of treatment failure and little progress has been achieved in the last decades. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg/Germany in November 2016 international experts presented and discussed recent developments in the field. Here, the potential of cellular therapies including unspecific and specific T cells, genetically modified T cells, CAR-T cells, NK-cells, and second allografting in prevention and treatment of relapse after alloSCT are summarized.

AB - Despite recent advances in reducing therapy-related mortality after allogeneic stem cell transplantation (alloSCT) relapse remains the major cause of treatment failure and little progress has been achieved in the last decades. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg/Germany in November 2016 international experts presented and discussed recent developments in the field. Here, the potential of cellular therapies including unspecific and specific T cells, genetically modified T cells, CAR-T cells, NK-cells, and second allografting in prevention and treatment of relapse after alloSCT are summarized.

KW - Journal Article

KW - Stem Cell Transplantation

KW - Recurrence

KW - Allografts

KW - Immunotherapy, Adoptive

KW - Humans

KW - Killer Cells, Natural/transplantation

KW - T-Lymphocytes/transplantation

U2 - 10.1038/s41409-018-0227-0

DO - 10.1038/s41409-018-0227-0

M3 - SCORING: Review article

C2 - 29795426

VL - 54

SP - 26

EP - 34

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 1

ER -